An intriguing possibility is that targeting the JAK/STAT pathway with clinically approved small-molecule inhibitors such as ruxolitinib, currently used treatment of graft-versus-host disease [97] and for other hematological disorders, could be tested as a prophylactic or preemptive approach for the prevention of EBV-driven PTLD. The gene discussed is SOAT1; the disease is graft versus host disease.